Reversal of lung cancer multidrug resistance by pH-responsive micelleplexes mediating co-delivery of siRNA and paclitaxel.
Identifieur interne : 000328 ( PubMed/Corpus ); précédent : 000327; suivant : 000329Reversal of lung cancer multidrug resistance by pH-responsive micelleplexes mediating co-delivery of siRNA and paclitaxel.
Auteurs : Haijun Yu ; Zhiai Xu ; Xianzhi Chen ; Leilei Xu ; Qi Yin ; Zhiwen Zhang ; Yaping LiSource :
- Macromolecular bioscience [ 1616-5195 ] ; 2014.
English descriptors
- KwdEn :
- Antineoplastic Agents, Phytogenic (administration & dosage), Antineoplastic Agents, Phytogenic (pharmacology), Apoptosis (drug effects), Apoptosis (genetics), Cell Line, Tumor, Chloroquine (pharmacology), Drug Carriers, Drug Resistance, Multiple (drug effects), Drug Resistance, Multiple (genetics), Drug Resistance, Neoplasm (drug effects), Drug Resistance, Neoplasm (genetics), Gene Knockdown Techniques, Humans, Hydrogen-Ion Concentration, Luciferases (genetics), Lung Neoplasms (drug therapy), Lung Neoplasms (genetics), Lung Neoplasms (pathology), Macrolides (pharmacology), Micelles, Nanoparticles (administration & dosage), Nanoparticles (chemistry), Paclitaxel (administration & dosage), Paclitaxel (pharmacology), Polymethacrylic Acids, Proto-Oncogene Proteins c-bcl-2 (genetics), RNA, Small Interfering (administration & dosage), RNA, Small Interfering (genetics), Transfection.
- MESH :
- chemical , administration & dosage : Antineoplastic Agents, Phytogenic, Paclitaxel, RNA, Small Interfering.
- chemical , genetics : Luciferases, Proto-Oncogene Proteins c-bcl-2, RNA, Small Interfering.
- chemical , pharmacology : Antineoplastic Agents, Phytogenic, Chloroquine, Macrolides, Paclitaxel.
- administration & dosage : Nanoparticles.
- chemistry : Nanoparticles.
- drug effects : Apoptosis, Drug Resistance, Multiple, Drug Resistance, Neoplasm.
- drug therapy : Lung Neoplasms.
- genetics : Apoptosis, Drug Resistance, Multiple, Drug Resistance, Neoplasm, Lung Neoplasms.
- pathology : Lung Neoplasms.
- Cell Line, Tumor, Drug Carriers, Gene Knockdown Techniques, Humans, Hydrogen-Ion Concentration, Micelles, Polymethacrylic Acids, Transfection.
Abstract
The recent advances in RNA interference (RNAi) technology provided novel and promising solutions for human cancer treatment. In this study, the application of dual pH-responsive cationic micellar nanoparticles for small interfering RNA (siRNA) and paclitaxel (PTX) co-delivery to overcome cancer multidrug resistance (MDR) is reported. The in vitro siRNA transfection shows that siRNA-luciferase (Luc) loaded micelleplexes efficiently silences Luc expression in various carcinoma cell lines. The Luc knockdown ability of the micelleplexes can be enhanced by choloquine (CQ) co-incubation. However, is abolished by bafilomycin-A1 (Baf-A1) treatment. The micelleplexes are further exploited for co-delivery of siRNA-Bcl-2 and PTX to Bcl-2 overexpressing A549 lung cancer cells (A549-Bcl-2). The experimental results show that the micelleplexes could sensitize A549-Bcl-2 cells to PTX via down-regulation of anti-apoptosis gene of Bcl-2, suggesting that PDMA-b-PDPA micelleplexes are promising nanovectors for siRNA and anti-cancer drug co-delivery to overcome cancer MDR.
DOI: 10.1002/mabi.201300282
PubMed: 23966347
Links to Exploration step
pubmed:23966347Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Reversal of lung cancer multidrug resistance by pH-responsive micelleplexes mediating co-delivery of siRNA and paclitaxel.</title><author><name sortKey="Yu, Haijun" sort="Yu, Haijun" uniqKey="Yu H" first="Haijun" last="Yu">Haijun Yu</name><affiliation><nlm:affiliation>Center of Pharmaceutics, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, 501 Haike Road, Shanghai, 201203, P. R. China.</nlm:affiliation></affiliation></author><author><name sortKey="Xu, Zhiai" sort="Xu, Zhiai" uniqKey="Xu Z" first="Zhiai" last="Xu">Zhiai Xu</name></author><author><name sortKey="Chen, Xianzhi" sort="Chen, Xianzhi" uniqKey="Chen X" first="Xianzhi" last="Chen">Xianzhi Chen</name></author><author><name sortKey="Xu, Leilei" sort="Xu, Leilei" uniqKey="Xu L" first="Leilei" last="Xu">Leilei Xu</name></author><author><name sortKey="Yin, Qi" sort="Yin, Qi" uniqKey="Yin Q" first="Qi" last="Yin">Qi Yin</name></author><author><name sortKey="Zhang, Zhiwen" sort="Zhang, Zhiwen" uniqKey="Zhang Z" first="Zhiwen" last="Zhang">Zhiwen Zhang</name></author><author><name sortKey="Li, Yaping" sort="Li, Yaping" uniqKey="Li Y" first="Yaping" last="Li">Yaping Li</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2014">2014</date><idno type="RBID">pubmed:23966347</idno><idno type="pmid">23966347</idno><idno type="doi">10.1002/mabi.201300282</idno><idno type="wicri:Area/PubMed/Corpus">000328</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000328</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Reversal of lung cancer multidrug resistance by pH-responsive micelleplexes mediating co-delivery of siRNA and paclitaxel.</title><author><name sortKey="Yu, Haijun" sort="Yu, Haijun" uniqKey="Yu H" first="Haijun" last="Yu">Haijun Yu</name><affiliation><nlm:affiliation>Center of Pharmaceutics, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, 501 Haike Road, Shanghai, 201203, P. R. China.</nlm:affiliation></affiliation></author><author><name sortKey="Xu, Zhiai" sort="Xu, Zhiai" uniqKey="Xu Z" first="Zhiai" last="Xu">Zhiai Xu</name></author><author><name sortKey="Chen, Xianzhi" sort="Chen, Xianzhi" uniqKey="Chen X" first="Xianzhi" last="Chen">Xianzhi Chen</name></author><author><name sortKey="Xu, Leilei" sort="Xu, Leilei" uniqKey="Xu L" first="Leilei" last="Xu">Leilei Xu</name></author><author><name sortKey="Yin, Qi" sort="Yin, Qi" uniqKey="Yin Q" first="Qi" last="Yin">Qi Yin</name></author><author><name sortKey="Zhang, Zhiwen" sort="Zhang, Zhiwen" uniqKey="Zhang Z" first="Zhiwen" last="Zhang">Zhiwen Zhang</name></author><author><name sortKey="Li, Yaping" sort="Li, Yaping" uniqKey="Li Y" first="Yaping" last="Li">Yaping Li</name></author></analytic><series><title level="j">Macromolecular bioscience</title><idno type="eISSN">1616-5195</idno><imprint><date when="2014" type="published">2014</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Antineoplastic Agents, Phytogenic (administration & dosage)</term><term>Antineoplastic Agents, Phytogenic (pharmacology)</term><term>Apoptosis (drug effects)</term><term>Apoptosis (genetics)</term><term>Cell Line, Tumor</term><term>Chloroquine (pharmacology)</term><term>Drug Carriers</term><term>Drug Resistance, Multiple (drug effects)</term><term>Drug Resistance, Multiple (genetics)</term><term>Drug Resistance, Neoplasm (drug effects)</term><term>Drug Resistance, Neoplasm (genetics)</term><term>Gene Knockdown Techniques</term><term>Humans</term><term>Hydrogen-Ion Concentration</term><term>Luciferases (genetics)</term><term>Lung Neoplasms (drug therapy)</term><term>Lung Neoplasms (genetics)</term><term>Lung Neoplasms (pathology)</term><term>Macrolides (pharmacology)</term><term>Micelles</term><term>Nanoparticles (administration & dosage)</term><term>Nanoparticles (chemistry)</term><term>Paclitaxel (administration & dosage)</term><term>Paclitaxel (pharmacology)</term><term>Polymethacrylic Acids</term><term>Proto-Oncogene Proteins c-bcl-2 (genetics)</term><term>RNA, Small Interfering (administration & dosage)</term><term>RNA, Small Interfering (genetics)</term><term>Transfection</term></keywords><keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Antineoplastic Agents, Phytogenic</term><term>Paclitaxel</term><term>RNA, Small Interfering</term></keywords><keywords scheme="MESH" type="chemical" qualifier="genetics" xml:lang="en"><term>Luciferases</term><term>Proto-Oncogene Proteins c-bcl-2</term><term>RNA, Small Interfering</term></keywords><keywords scheme="MESH" type="chemical" qualifier="pharmacology" xml:lang="en"><term>Antineoplastic Agents, Phytogenic</term><term>Chloroquine</term><term>Macrolides</term><term>Paclitaxel</term></keywords><keywords scheme="MESH" qualifier="administration & dosage" xml:lang="en"><term>Nanoparticles</term></keywords><keywords scheme="MESH" qualifier="chemistry" xml:lang="en"><term>Nanoparticles</term></keywords><keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>Apoptosis</term><term>Drug Resistance, Multiple</term><term>Drug Resistance, Neoplasm</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Lung Neoplasms</term></keywords><keywords scheme="MESH" qualifier="genetics" xml:lang="en"><term>Apoptosis</term><term>Drug Resistance, Multiple</term><term>Drug Resistance, Neoplasm</term><term>Lung Neoplasms</term></keywords><keywords scheme="MESH" qualifier="pathology" xml:lang="en"><term>Lung Neoplasms</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Cell Line, Tumor</term><term>Drug Carriers</term><term>Gene Knockdown Techniques</term><term>Humans</term><term>Hydrogen-Ion Concentration</term><term>Micelles</term><term>Polymethacrylic Acids</term><term>Transfection</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">The recent advances in RNA interference (RNAi) technology provided novel and promising solutions for human cancer treatment. In this study, the application of dual pH-responsive cationic micellar nanoparticles for small interfering RNA (siRNA) and paclitaxel (PTX) co-delivery to overcome cancer multidrug resistance (MDR) is reported. The in vitro siRNA transfection shows that siRNA-luciferase (Luc) loaded micelleplexes efficiently silences Luc expression in various carcinoma cell lines. The Luc knockdown ability of the micelleplexes can be enhanced by choloquine (CQ) co-incubation. However, is abolished by bafilomycin-A1 (Baf-A1) treatment. The micelleplexes are further exploited for co-delivery of siRNA-Bcl-2 and PTX to Bcl-2 overexpressing A549 lung cancer cells (A549-Bcl-2). The experimental results show that the micelleplexes could sensitize A549-Bcl-2 cells to PTX via down-regulation of anti-apoptosis gene of Bcl-2, suggesting that PDMA-b-PDPA micelleplexes are promising nanovectors for siRNA and anti-cancer drug co-delivery to overcome cancer MDR. </div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">23966347</PMID><DateCompleted><Year>2014</Year><Month>10</Month><Day>28</Day></DateCompleted><DateRevised><Year>2015</Year><Month>11</Month><Day>19</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1616-5195</ISSN><JournalIssue CitedMedium="Internet"><Volume>14</Volume><Issue>1</Issue><PubDate><Year>2014</Year><Month>Jan</Month></PubDate></JournalIssue><Title>Macromolecular bioscience</Title><ISOAbbreviation>Macromol Biosci</ISOAbbreviation></Journal><ArticleTitle>Reversal of lung cancer multidrug resistance by pH-responsive micelleplexes mediating co-delivery of siRNA and paclitaxel.</ArticleTitle><Pagination><MedlinePgn>100-9</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1002/mabi.201300282</ELocationID><Abstract><AbstractText>The recent advances in RNA interference (RNAi) technology provided novel and promising solutions for human cancer treatment. In this study, the application of dual pH-responsive cationic micellar nanoparticles for small interfering RNA (siRNA) and paclitaxel (PTX) co-delivery to overcome cancer multidrug resistance (MDR) is reported. The in vitro siRNA transfection shows that siRNA-luciferase (Luc) loaded micelleplexes efficiently silences Luc expression in various carcinoma cell lines. The Luc knockdown ability of the micelleplexes can be enhanced by choloquine (CQ) co-incubation. However, is abolished by bafilomycin-A1 (Baf-A1) treatment. The micelleplexes are further exploited for co-delivery of siRNA-Bcl-2 and PTX to Bcl-2 overexpressing A549 lung cancer cells (A549-Bcl-2). The experimental results show that the micelleplexes could sensitize A549-Bcl-2 cells to PTX via down-regulation of anti-apoptosis gene of Bcl-2, suggesting that PDMA-b-PDPA micelleplexes are promising nanovectors for siRNA and anti-cancer drug co-delivery to overcome cancer MDR. </AbstractText><CopyrightInformation>© 2014 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Yu</LastName><ForeName>Haijun</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Center of Pharmaceutics, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, 501 Haike Road, Shanghai, 201203, P. R. China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Xu</LastName><ForeName>Zhiai</ForeName><Initials>Z</Initials></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Xianzhi</ForeName><Initials>X</Initials></Author><Author ValidYN="Y"><LastName>Xu</LastName><ForeName>Leilei</ForeName><Initials>L</Initials></Author><Author ValidYN="Y"><LastName>Yin</LastName><ForeName>Qi</ForeName><Initials>Q</Initials></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Zhiwen</ForeName><Initials>Z</Initials></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Yaping</ForeName><Initials>Y</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2013</Year><Month>08</Month><Day>21</Day></ArticleDate></Article><MedlineJournalInfo><Country>Germany</Country><MedlineTA>Macromol Biosci</MedlineTA><NlmUniqueID>101135941</NlmUniqueID><ISSNLinking>1616-5187</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000972">Antineoplastic Agents, Phytogenic</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D004337">Drug Carriers</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018942">Macrolides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D008823">Micelles</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011109">Polymethacrylic Acids</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D019253">Proto-Oncogene Proteins c-bcl-2</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D034741">RNA, Small Interfering</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C570790">poly(2-(dimethylamino)ethyl methacrylate)-block-poly(2-(diisopropylamino)ethyl methacrylate)</NameOfSubstance></Chemical><Chemical><RegistryNumber>886U3H6UFF</RegistryNumber><NameOfSubstance UI="D002738">Chloroquine</NameOfSubstance></Chemical><Chemical><RegistryNumber>88899-55-2</RegistryNumber><NameOfSubstance UI="C040929">bafilomycin A1</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 1.13.12.-</RegistryNumber><NameOfSubstance UI="D008156">Luciferases</NameOfSubstance></Chemical><Chemical><RegistryNumber>P88XT4IS4D</RegistryNumber><NameOfSubstance UI="D017239">Paclitaxel</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000972" MajorTopicYN="N">Antineoplastic Agents, Phytogenic</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017209" MajorTopicYN="N">Apoptosis</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D045744" MajorTopicYN="N">Cell Line, Tumor</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002738" MajorTopicYN="N">Chloroquine</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004337" MajorTopicYN="N">Drug Carriers</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018432" MajorTopicYN="N">Drug Resistance, Multiple</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019008" MajorTopicYN="N">Drug Resistance, Neoplasm</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D055785" MajorTopicYN="N">Gene Knockdown Techniques</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006863" MajorTopicYN="N">Hydrogen-Ion Concentration</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008156" MajorTopicYN="N">Luciferases</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008175" MajorTopicYN="N">Lung Neoplasms</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018942" MajorTopicYN="N">Macrolides</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008823" MajorTopicYN="N">Micelles</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D053758" MajorTopicYN="N">Nanoparticles</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017239" MajorTopicYN="N">Paclitaxel</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011109" MajorTopicYN="N">Polymethacrylic Acids</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019253" MajorTopicYN="N">Proto-Oncogene Proteins c-bcl-2</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D034741" MajorTopicYN="N">RNA, Small Interfering</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="Y">administration & dosage</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014162" MajorTopicYN="N">Transfection</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Paclitaxel</Keyword><Keyword MajorTopicYN="N">lung cancer</Keyword><Keyword MajorTopicYN="N">micelleplexes</Keyword><Keyword MajorTopicYN="N">multidrug resistance</Keyword><Keyword MajorTopicYN="N">pH-responsive</Keyword><Keyword MajorTopicYN="N">siRNA</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2013</Year><Month>06</Month><Day>08</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2013</Year><Month>07</Month><Day>13</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2013</Year><Month>8</Month><Day>23</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2013</Year><Month>8</Month><Day>24</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2014</Year><Month>10</Month><Day>29</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">23966347</ArticleId><ArticleId IdType="doi">10.1002/mabi.201300282</ArticleId></ArticleIdList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/ChloroquineV1/Data/PubMed/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000328 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd -nk 000328 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= ChloroquineV1
|flux= PubMed
|étape= Corpus
|type= RBID
|clé= pubmed:23966347
|texte= Reversal of lung cancer multidrug resistance by pH-responsive micelleplexes mediating co-delivery of siRNA and paclitaxel.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/RBID.i -Sk "pubmed:23966347" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd \
| NlmPubMed2Wicri -a ChloroquineV1
| This area was generated with Dilib version V0.6.33. |  |